MD
MDT.US Medtronic PLC
- Market cap
- USD 132B
- P/E
- 25.3x
- P/B
- 2.62x
- ROE
- 11.7%
- Dividend yield
- 2.77%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is MDT.US undervalued?
Graham numberMDT.US trades 71.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medtronic PLC fundamental analysis
No fundamental analysis for Medtronic PLC yet.
Medtronic PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medtronic PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablati…
Full company profileMedtronic PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medtronic PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 29.7B | 30.0B | 30.6B | 28.9B | 30.1B | 31.7B | 31.2B | 32.4B | 33.5B | 36.4B | 39.0B |
| Gross Profit | 20.4B | 20.9B | 21.4B | 19.5B | 19.6B | 21.5B | 20.5B | 21.1B | 21.9B | 23.6B | 25.4B |
| Operating Income | 5.38B | 6.64B | 6.27B | 4.79B | 4.48B | 5.75B | 5.49B | 5.14B | 5.96B | 6.47B | 7.06B |
| EBITDA | 8.61B | 9.47B | 9.30B | 7.81B | 7.52B | 8.78B | 8.70B | 8.20B | 9.22B | 9.81B | 10.7B |
| Net Income | 4.03B | 3.10B | 4.63B | 4.79B | 3.61B | 5.04B | 3.76B | 3.68B | 4.66B | 4.80B | 5.88B |
| EPS | 2.89 | 2.27 | 3.41 | 3.54 | 2.66 | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 | 4.58 |
| Balance Sheet | |||||||||||
| Total Assets | 99.8B | 91.4B | 89.7B | 90.7B | 93.1B | 91.0B | 90.9B | 90.0B | 91.7B | 93.0B | 93.3B |
| Total Liabilities | 49.4B | 40.6B | 39.5B | 39.8B | 41.5B | 38.3B | 39.3B | 39.6B | 43.4B | 43.0B | 42.5B |
| Shareholders' Equity | 50.3B | 50.7B | 50.1B | 50.7B | 51.4B | 52.6B | 51.5B | 50.2B | 48.0B | 49.5B | 50.2B |
| Cash & Short-term Investments | 13.7B | 11.2B | 9.85B | 10.9B | 10.8B | 10.6B | 7.96B | 8.01B | 8.97B | 9.22B | 8.82B |
| Total Debt | 33.4B | 25.8B | 25.3B | 24.8B | 26.4B | 24.1B | 24.4B | 25.0B | 28.5B | 28.0B | 28.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.88B | 4.68B | 7.01B | 7.23B | 6.24B | 7.35B | 6.04B | 6.79B | 7.04B | 7.33B | 7.17B |
| Capital Expenditure | 1.25B | 1.07B | 1.13B | 1.21B | 1.36B | 1.37B | 1.46B | 1.59B | 1.86B | 1.90B | 2.01B |
| Free Cash Flow | 5.63B | 3.62B | 5.87B | 6.02B | 4.89B | 5.98B | 4.58B | 5.20B | 5.19B | 5.43B | 5.16B |
| Ratios | |||||||||||
| ROE | 8.0% | 6.1% | 9.2% | 9.4% | 7.0% | 9.6% | 7.3% | 7.3% | 9.7% | 9.7% | 11.7% |
| ROA | 4.0% | 3.4% | 5.2% | 5.3% | 3.9% | 5.5% | 4.1% | 4.1% | 5.1% | 5.2% | 6.3% |
| Net Profit Margin | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% | 15.1% |
| Debt to Equity | 0.66x | 0.51x | 0.51x | 0.49x | 0.51x | 0.46x | 0.47x | 0.50x | 0.59x | 0.57x | 0.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medtronic PLC dividends
- Dividend yield
- 2.77%
- Forward dividend
- 2.88 USD
- Payout ratio
- 75.8%
- Ex-dividend date
- Sep 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 3.64B | 2.83 | 75.8% |
| 2025 | USD 3.59B | 2.78 | 77.0% |
| 2024 | USD 3.67B | 2.76 | 99.7% |
| 2023 | USD 3.62B | 2.71 | 96.2% |
| 2022 | USD 3.38B | 2.50 | 67.1% |
| 2021 | USD 3.12B | 2.31 | 86.6% |
| 2020 | USD 2.89B | 2.14 | 60.4% |
| 2019 | USD 2.69B | 1.98 | 58.2% |
| 2018 | USD 2.49B | 1.82 | 80.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 27, 1999.
Who owns Medtronic PLC
- Insiders 1.19%
- Institutions 88.35%
- Public & others 10.46%
- Shares outstanding 1.28B
- Free float 1.28B
Top funds holding MDT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 40.6M | 3.17% | -0.43% | Sep 2026 |
| Vanguard 500 Index Investor | 33.6M | 2.63% | -1.45% | Sep 2026 |
| Fidelity 500 Index | 16.6M | 1.30% | -0.18% | Sep 2026 |
| iShares Core S&P 500 ETF | 16.3M | 1.28% | +0.17% | Oct 2026 |
| State Street® SPDR® S&P 500® ETF | 15.0M | 1.17% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 12.2M | 0.95% | -0.70% | Sep 2026 |
| First Eagle Global A | 9.06M | 0.71% | 0.00% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 8.95M | 0.70% | +0.88% | Oct 2026 |
| American Funds Income Fd of Amer A | 8.46M | 0.66% | +38.15% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 7.24M | 0.57% | -0.35% | Sep 2026 |
| Vanguard Institutional Index I | 6.77M | 0.53% | -1.33% | Sep 2026 |
| Capital Group Dividend Value ETF | 5.37M | 0.42% | 0.00% | Oct 2026 |
| Vanguard High Dividend Yield ETF | 5.22M | 0.41% | +0.28% | Sep 2026 |
| Vanguard Windsor II Inv | 5.08M | 0.40% | -4.36% | Sep 2026 |
| Franklin Income A1 | 5.00M | 0.39% | 0.00% | Sep 2026 |
| WCM Focused International Growth Instl | 4.93M | 0.39% | +13.29% | Sep 2026 |
| Dodge & Cox Stock I | 4.90M | 0.38% | -14.62% | Sep 2026 |
| Columbia Dividend Income Inst | 4.88M | 0.38% | -0.58% | Sep 2026 |
| DWS Top Dividende LD | 4.80M | 0.38% | +0.00% | Sep 2026 |
| State Street® SPDR® S&P® Dividend ETF | 4.47M | 0.35% | 0.00% | Oct 2026 |
Top institutions holding MDT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 114M | 8.91% | +0.74% | Jun 2026 |
| Vanguard Capital Management, LLC | 83.8M | 6.55% | +0.58% | Jun 2026 |
| State Street Corp | 63.4M | 4.95% | +2.69% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 34.1M | 2.66% | +1.82% | Jun 2026 |
| Geode Capital Management, LLC | 30.2M | 2.36% | +5.07% | Jun 2026 |
| JPMorgan Chase & Co | 27.8M | 2.17% | -45.49% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 27.6M | 2.15% | +174.45% | Jun 2026 |
| Bank of America Corp | 21.3M | 1.67% | -18.04% | Jun 2026 |
| Massachusetts Financial Services Company | 19.9M | 1.55% | -7.30% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 19.4M | 1.52% | -6.14% | Jun 2026 |
| Deutsche Bank AG | 18.4M | 1.44% | -2.91% | Jun 2026 |
| Amvescap Plc. | 17.9M | 1.40% | +6.54% | Jun 2026 |
| Franklin Templeton Inc | 17.6M | 1.37% | +23.81% | Jun 2026 |
| NORGES BANK | 16.6M | 1.29% | -3.85% | Jun 2026 |
| Royal Bank of Canada | 16.0M | 1.25% | +13.02% | Jun 2026 |
| Bank of New York Mellon Corp | 14.7M | 1.15% | -5.21% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 12.9M | 1.01% | +176.70% | Jun 2026 |
| Capital Research Global Investors | 12.1M | 0.95% | -8.69% | Sep 2026 |
| Northern Trust Corp | 11.6M | 0.91% | -3.41% | Jun 2026 |
| Ameriprise Financial Inc | 11.6M | 0.90% | -3.46% | Jun 2026 |
Medtronic PLC company profile
- Company name
- Medtronic PLC
- Ticker
- MDT.US
- ISIN
- IE00BTN1Y115
- Exchange
- USA Stocks
- Listed since
- Jan 13, 1978
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 95,000
- Fiscal year end
- April
- Address
- Building Two, Galway, Ireland, H91 4K49
- Phone
- 353 1 438 1700
- Website
- medtronic.com
About Medtronic PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys
Medtronic PLC management
10- Mr. Geoffrey Straub MarthaChairman of the Board & CEO · born 1970
- Mr. Michael MarinaroPresident and President of Medical Surgical Portfolio, Americas & Global Commercial Ops · born 1971
- Mr. Thierry PietonExecutive VP & CFO · born 1970
- Ms. Michelle QuinnExecutive VP, General Counsel & Secretary · born 1969
- Mr. Rogerio BrancoSVP & Chief Operations and Supply Chain Officer
- Ms. Denise L. BlomquistVP, Global Controller & Chief Accounting Officer
- Dr. Laura Mauri M.D., M.Sc.Senior VP and Chief Scientific & Medical Officer · born 1970
- Ms. Ingrid GoldbergVice President & Head of Investor Relations
- Mr. Matthew R. WalterSenior Vice President of Human Resources, IT and Global Communications & Corporate Marketing · born 1979
- Mr. Alex GuSenior VP & President of Greater China Region